MeSH D064129 - castration-resistant prostatic neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Abiraterone | Abiraterone |  | 2018-10-31 |  |  |
| Glenmark Pharmaceuticals | Abiraterone | Abiraterone |  | 2019-10-16 |  |  |
| Mylan | Abiraterone | Abiraterone |  | 2018-10-31 |  |  |
| Abiraterone | Abiraterone Mylan |  | 2021-08-20 |  |  | |
| Johnson & Johnson | Abiraterone | Zytiga |  | 2011-04-28 | $823 M | Q2/23-Q1/24 |
| Niraparib, Abiraterone | Akeega | 2027-08-12 | 2023-08-11 |  |  | |
| Novartis | Lutetium (177lu) vipivotide tetraxetan | Pluvicto |  | 2022-12-09 | $250 M | Q2/22-Q2/23 |
| Bayer | Darolutamide | Nubeqa |  | 2020-03-27 |  |  |
| Dr Reddys Laboratories | Abiraterone | Abiraterone |  | 2020-05-18 |  |  |
| Rising Pharmaceuticals | Abiraterone | Abiraterone |  | 2019-02-25 |  |  |
| Sun Pharmaceutical Industries | Abiraterone | Yonsa | 2034-03-17 | 2018-05-22 |  |  |
| Apotex | Abiraterone | Abiraterone |  | 2018-10-31 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
52%68/132
Phase 2
27%31/116
Phase 3
32%12/37
Approved: 3Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use